Tomosynthesis Reduces Mammogram Call-Backs for Additional Testing Interview with Dr. Brian Haas MD Department of Diagnostic Radiology,Yale University School of Medicine, New Haven, CT
Dr. Brian Haas MD
Department of Diagnostic Radiology,Yale University School of Medicine, New Haven, CT What are the main findings of the study?

Dr. Haas: We found that tomosynthesis helped to reduce the number of women who undergo a screening mammogram and are called back for additional imaging and testing. Specifically, the greatest reductions in patients being called back were seen in younger patients and those with dense breasts. Tomosynthesis is analogous to a 3D mammogram, and improves contrast of cancers against the background breast parenchyma. Were any of the findings unexpected?

Dr. Haas: We were surprised that when we performed a regression analysis to control for various confounding factors, that the strength of our findings actually increased some. Following the regression analysis, both breast density and patient age remained independent predictors of being called back from mammography. What should clinicians and patients take away from your report?

Dr. Haas: Mammography is the only breast screening modality that has been proven to save lives. Now we have a technology that is enhancing mammography, that is making something that is really good even better. It is also important to recognize that tomosynthesis had the greatest benefit in patients with dense breasts and young patients. Patients with dense breasts are at increased risk for breast cancer. Meanwhile, there is controversy about screening younger women for breast cancer secondary to the false positive results (ie increased recall rate). Tomosynthesis is particularly strengthening the performance of mammography in these two challenging populations. What recommendations do you have for future research as a result of this study?

Dr. Haas: We also want to know how tomosynthesis is affecting our ability to detect cancer. We have seen tomosynthesis identify cancers that otherwise would not have been apparent on the conventional mammogram, but the numbers in our study were too small to show an impact on the cancer detection rate. We are collecting more patients to study this further.

Comparison of Tomosynthesis Plus Digital Mammography and Digital Mammography Alone for Breast Cancer Screening

Tomosynthesis reduces breast cancer screening recall rate

OAK BROOK, Ill. – Digital tomosynthesis is an effective tool for reducing the recall rate in breast cancer screening, according to a new study published online in the journal Radiology.

Digital mammography is the gold standard for breast cancer screening, but may yield suspicious findings that turn out not to be cancer. These false-positive findings are associated with a higher recall rate, or the rate at which women are called back for additional imaging or biopsy.

Digital breast tomosynthesis has shown promise at reducing recall rates, particularly in younger women and in those with dense breast tissue. Tomosynthesis is similar to mammography in that it relies on ionizing radiation to generate images of the breast. However, unlike conventional mammography, tomosynthesis allows for three-dimensional (3-D) reconstruction of the breast tissue, which can then be viewed as sequential slices through the breast.

“Tomosynthesis increases the conspicuity of cancers by removing superimposed and overlapping tissue from the view,” said Brian M. Haas, M.D., from Yale University School of Medicine in New Haven, Conn.

In the study, Dr. Haas worked with Liane E. Philpotts, M.D., also of Yale University, and other colleagues to compare screening recall rates and cancer detection rates in two groups of women: those who received conventional digital mammography alone and those who had tomosynthesis in addition to mammography.

Of the 13,158 patients who underwent screening mammography, 6,100 received tomosynthesis. The cancer detection rate was 5.7 per 1,000 in patients receiving tomosynthesis, compared with 5.2 per 1,000 in patients receiving mammography alone. The addition of tomosynthesis resulted in a 30 percent reduction in the overall recall rate, from 12.0 percent for mammography alone to 8.4 percent in the tomosynthesis group.

“All age groups and breast densities had reduced risk for recall in the tomosynthesis group,” Dr. Haas said. “Women with dense breasts and those younger than age 50 particularly benefited from tomosynthesis.”

Lower recall rates help reduce patient anxiety and also reduce costs from additional diagnostic examinations, Dr. Haas said.

Tomosynthesis has one significant drawback: a radiation dose approximately double that of digital mammography alone. However, Dr. Haas noted that new technology approved by the U.S. Food and Drug Administration could reduce the dose.

“The technology involves taking the tomosynthesis data and collapsing it into planar imaging that resembles 2-D mammography,” he said. “It has the potential to eliminate the need for acquisition of the conventional 2-D images in addition to the tomosynthesis images.”

The research group is currently in the process of comparing the cancers found on tomosynthesis with those found on mammography. They are also tracking the study group for interval cancers—those that develop in the interval between screenings—to make sure that the reduced recall rate associated with tomosynthesis is not resulting in missed cancers.


“Comparison of Tomosynthesis Plus Digital Mammography and Digital Mammography Alone for Breast Cancer Screening.” Collaborating with Drs. Haas and Philpotts were Vivek Kalra, M.D., Jaime Geisel, M.D., Madhavi Raghu, M.D., and Melissa Durand, M.D.



Last Updated on November 3, 2014 by Marie Benz MD FAAD